Gene dosage of the apolipoprotein E (APOE) ε4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the ε2 allele, in addition to the dose effect of the ε4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of ε4 alleles, risk of AD is lowest in subjects with the ε2/ε3 genotype, with an additional 23% of AD attributable to the absence of an ε2 allele. The opposite actions of the ε2 and ε4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Advisory Panel on Alzheimer's Disease. Fourth Report of the Advisory Panel on Alzheimer's Disease, 1992 1 (NIH Pub. No. 93–352, U. S. Govt. Print. Off., Washington D. C., 1993).
Breteler, M.B., Claus, J.L., Van Duijn, C.M., Launer, L.J. & Hofman, A. Epidemiology of Alzheimer's disease. Epidemiol. Rev. 14, 59–82 (1992).
Schellenberg, G.D. et al. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258, 668–671 (1992).
St George-Hyslop, P. et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nature Genet. 2, 330–334 (1992).
van Broeckhoven, C. et al. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3 Nature Genet. 2, 335–339 (1992).
St George-Hyslop, P.H. et al. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 235, 885–890 (1987).
Goate, A. et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704–706 (1991).
Appel, S. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, Parkinsonism, and Alzheimer disease. Ann. Neurol. 20, 499–505 (1981).
Breitner, J.C.S. & Folstein, M.F. Familial Alzheimer dementia: a prevalent disorder with specific clinical features. Psychol. Med. 14, 63–80 (1984).
Mohs, R.C. et al. Alzheimer's disease. Morbid risk among first-degree relatives approximates 50% by 90 years of age. Arch. gen. Psychiatry 44, 405–408 (1987).
Breitner, J.C.S., Silverman, J.M., Mohs, R.C. & Davis, K.L. Familial aggregation in Alzheimer's disease: comparison of risk among relatives of early-and late-onset cases, andamongmaleand female relatives in successive generations. Neurology 38, 207–212 (1988).
Huff, F.J., Auerbach, J., Chakravarti, A. & Boller, F. Risk of dementia in relatives with Alzheimer's disease. Neurology 38, 786–790 (1988).
Farrer, L.A. et al. Transmissionandage-at-onset patterns in familial Alzheimer's disease: evidence for heterogeneity. Neurology 40, 395–403 (1990).
St George-Hyslop, P.H. et al. Familial Alzheimer's disease: progress and problems. Neurobiol. Aging 10, 417–425 (1989).
Folstein, M.F. et al. Dementia: case ascertainment in a community survey. J. Gerontol. 46, M132–138 (1991).
Pericak-Vance, M.A. et al. Genetic linkage studies in Alzheimer's disease families. Exp. Neurol. 102, 271–279 (1988).
Khachaturian, Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42, 1097–1105 (1985).
McKhann, G. et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939–944 (1984).
Pericak-Vance, M.A. et al. Linkage studies in familial Alzheimer's disease: evidence for chromosome 19 linkage. Am. J. hum. Genet. 48, 1034–1050 (1991).
Saunders, A.M. et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1462–1472 (1993).
Strittmatter, W.J. et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type ε4 allele in late-onset familial Alzheimer's disease. Proc. natn. Acad. Sci. U.S.A. 90, 1977–1981 (1993).
Payami, H. et al. Apolipoprotein E genotype and Alzheimer's disease. Lancet 342, 738 (1993).
Borgaonkar, D.S. et al. Linkage of late-onset Alzheimer disease with apolipoprotein E type ε4 on chromosome 19 confirmed by family studies. Lancet 342, 625 (1993).
Liddell, M. et al. Confirmation of association between the ε4 allele of apolipoprotein E and Alzheimer's disease. J. med. Genet. (in the press).
Mayeux, R. et al. The apolipoprotein e4 allele in patients with Alzheimer's disease. Ann. Neurology 34, 752–754 (1993).
Rebeck, G.W., Reiter, J.S., Strickland, D.K. & Hyman, B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575–580 (1993).
Poirier, J. et al. Apolipoprotein E and Alzheimer's disease. Lancet 342, 697–699 (1993).
Corder, E.H. et al. Apolipoprotein E gene dose and the risk of Alzheimer disease in late onset families. Science 261, 921–923 (1993).
Utermann, G., Langenbeck, U., Beisiegel, U. & Weber, W. Genetics of the apolipoprotein E system in man. Am. J. hum. Genet. 32, 339–347 (1980).
Mahley, R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622–628 (1988).
Hardy, J. & the Alzheimer's Disease Collaborative Group. Apolipoprotein E and Alzheimer's Disease. Lancet 342, 737–738 (1993).
Strittmatter, W.J. et al. Binding of human apolipoprotein E to synthetic amyloid β-peptide: isoform-specific effects and implications for late-onset al Azheimer disease. Proc. natn. Acad. Sci. U.S.A. 80, 8098–8102 (1993).
Schmechel, D.E. et al. Increased amyloid (β-peptide deposition in cerebral cortex as aconsequence of apolipoprotein Egenotype in late-onset Alzheimer disease. Proc. natn. Acad. Sci. U.S.A. 90, 9649–9653 (1993).
Saunders, A.M. et al. Apolipoprotein E ε4 allele distributions in late-onset Alzheimer disease and in other amyloid-forming diseases. Lancet 342, 710–711 (1993).
Strittmatter, W.J. et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimerdisease brain asafunction of apolipoprotein E genotype. Exp. Neurol. 125, 163–171 (1994).
Schellenberg, G.D. et al. Genetic association and linkage analysis of the apolipoprotein Cll locus and familial Alzheimer's disease. Ann. Neurol. 31, 223–227 (1992).
Myklebost, O. & Rogne, S. A physical map of the apolipoprotein gene cluster on chromosome 19. Hum. Genet. 78, 244–247 (1988).
Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
Dausset, J. et al. Centre D'Etude du Polymorphisme Humain (CEPH): collaborative genetic mapping of the human genome. Genomics 6, 575–577 (1990).
Kleinbaum, D.G., Kupper, L.L. & Morgenstern, H. Epidemiologic Research. 283–311, 419–445 (Van Nostrand Reinhold, New York, 1982).
SAS Technical Report P-200. Release 6.04. 175–230 (SAS Institute, Gary, 1990).
Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
SAS Technical Report P-217. Version 6.0 37–41 (SAS Institute, Gary, 1991).
About this article
Cite this article
Corder, E., Saunders, A., Risch, N. et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7, 180–184 (1994). https://doi.org/10.1038/ng0694-180
Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer’s Disease: Targeting Mitochondria for Diagnosis and Prevention
Antioxidants & Redox Signaling (2020)
Alzheimer's disease pathology in ApoE transgenic mouse models: The Who, What, When, Where, Why, and How
Neurobiology of Disease (2020)
Interaction Between Odor Identification Deficit and APOE4 Predicts 6-Year Cognitive Decline in Elderly Individuals
Behavior Genetics (2020)
Nature Reviews Neurology (2020)
Neurobiology of Disease (2020)